Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
about
Dietary advice for people with schizophreniaAripiprazole for neuroleptic induced hyperprolactinaemiaReview of depot aripiprazole for schizophreniaEffect of atypical antipsychotics on fetal growth: is the placenta involved?Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patientsSignificant weight loss following clozapine use, how is it possible? A case report and review of published cases and literature relevant to the subjectCurrent Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive ReviewRisperidone and the 5-HT2A receptor antagonist M100907 improve probabilistic reversal learning in BTBR T + tf/J miceTorsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across EuropeEffectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohortAn evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapineThe Psychosis Recent Onset GRoningen Survey (PROGR-S): defining dimensions and improving outcomes in early psychosisCurcumin Mitigates the Intracellular Lipid Deposit Induced by Antipsychotics In VitroWeight Loss in Patients with Dementia: Considering the Potential Impact of Pharmacotherapy.Clinical utility of the risperidone formulations in the management of schizophrenia.Oxytocin in schizophrenia: a review of evidence for its therapeutic effects.Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials.Exercise therapy in adults with serious mental illness: a systematic review and meta-analysisMetabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general populationBergamot (Citrus bergamia) Essential Oil Inhalation Improves Positive Feelings in the Waiting Room of a Mental Health Treatment Center: A Pilot Study.The First Negative Allosteric Modulator for Dopamine D2 and D3 Receptors, SB269652 May Lead to a New Generation of Antipsychotic DrugsDoes participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians.Very low rates of screening for metabolic syndrome among patients with severe mental illness in Durban, South Africa.A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia.Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.A multiple imputation strategy for sequential multiple assignment randomized trialsGlucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits.Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approachAntipsychotic Maintenance Treatment: Time to Rethink?Lipid-lowering effects of tetradecylthioacetic acid in antipsychotic-exposed, female rats: challenges with long-term treatmentTreatment response to the RENEW weight loss intervention in schizophrenia: impact of intervention settingPhysical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.Factors associated with non evidence-based prescribing of antipsychoticsThe World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder.
P2860
Q24186009-0426517D-4CD5-4741-B4AF-7E79EAFD21A4Q24197806-BEFBCDFF-B32A-4B66-A414-6B905CBD1980Q27008464-78FA1344-01DD-4A6B-A895-EDECA5090649Q27012948-972935FF-4861-42F4-B3F0-3EF83B405289Q27027832-E426C265-586B-4A13-A1E4-1CD3E8154DEAQ28073082-6387834A-C388-4DBF-8B82-E08755FA07E1Q28079821-304FD5D5-7E26-430A-9658-B03C229508A1Q28397643-6DDD2B42-0FD4-49B5-9080-70C52C16B02BQ28535299-489A6142-1190-4D62-B1FC-0C7349330D02Q28538703-D7EBCB09-AE8D-4977-95B8-8B99A32F7A2AQ28543222-FF0CAC65-9DC2-4B58-992E-79882CED0126Q28545094-BB70012B-B519-4322-AD99-2F1505CF9566Q28550570-9253C217-21E5-4DAC-92DD-FA7AE249DB0BQ30234535-DF3750A8-8B54-48B9-8CC6-77EC631FB72EQ30429721-0015B8E6-300D-4B40-A652-8C508934502CQ30453929-8B5433A0-4BB4-4D27-B7E0-270E71E23E39Q30459096-8CCBAE1D-CA78-409E-9D54-ACEC2CE4629DQ30490054-2FBBA657-4742-4D63-A688-51287CE96E91Q33600284-31CDE1C5-F947-4B97-B6F4-3917376589BAQ33622056-46B3D690-360E-4FF0-B26B-C8D6C2A5B380Q33698223-EB4F48C0-2DF3-43A0-8596-CE208E19B2B5Q33707895-8E412FD2-5840-4B16-B117-E4D6FD1DB89DQ33895407-3644D269-28DF-4C4A-ADB5-957BC3085873Q34033259-15B13473-D83A-41C2-9C2D-FBCA3AE07BB3Q34109049-C6741C92-114C-49D2-9F88-2C6972D0818CQ34224372-DA8F66E1-B035-4848-AD40-A884FAECABBDQ34248044-54307C56-180D-45B4-A0C0-E707EEADA0A1Q34274859-7FD9B96B-9B19-491D-8BFB-CD180FB1F94BQ34287887-EB97BF59-9D7E-4742-A798-DB4E00FC41BCQ34379379-57B5B520-203C-4D53-9266-C936DC59B408Q34464293-A83F32EF-2CE1-444C-A661-1DA0629D08FDQ34488215-09412072-0332-49C6-908E-3C14238523EFQ34506022-935D6579-12A9-4C44-B852-5DD3B44972D1Q34619959-974A71F2-7728-4A29-83F8-C651252DFC1BQ34623350-168FA39D-29D9-45C3-8C50-E7C3443EFA13Q34631699-978A3B15-E89F-4822-9D3E-D7E4775E7B01Q34640811-AAD0E3A2-63BE-4832-BFC6-87A2BDF78557Q34641561-DBE00576-09B6-4577-9D72-71D24844313CQ34642808-71A4CB77-21C5-465F-953F-BC63AB763B1CQ34649187-03251916-3369-4085-99F0-4E4AF9BEA133
P2860
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Head-to-head comparisons of me ...... atic review and meta-analysis.
@ast
Head-to-head comparisons of me ...... atic review and meta-analysis.
@en
Head-to-head comparisons of me ...... atic review and meta-analysis.
@nl
type
label
Head-to-head comparisons of me ...... atic review and meta-analysis.
@ast
Head-to-head comparisons of me ...... atic review and meta-analysis.
@en
Head-to-head comparisons of me ...... atic review and meta-analysis.
@nl
prefLabel
Head-to-head comparisons of me ...... atic review and meta-analysis.
@ast
Head-to-head comparisons of me ...... atic review and meta-analysis.
@en
Head-to-head comparisons of me ...... atic review and meta-analysis.
@nl
P2093
P2860
P1476
Head-to-head comparisons of me ...... atic review and meta-analysis.
@en
P2093
Claudia Asenjo Lobos
Franziska Schmid
Heike Hunger
John M Davis
Katja Komossa
Sandra Schwarz
Stefan Leucht
Werner Kissling
P2860
P304
P356
10.1016/J.SCHRES.2010.07.012
P407
P577
2010-08-07T00:00:00Z